Supplementary Fig. 2 from A Phase 1/2 Multicenter Randomized Trial of Local Ablation Plus Toripalimab Versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma | Synapse
September 16, 2024
Supplementary Fig. 2 from A Phase 1/2 Multicenter Randomized Trial of Local Ablation Plus Toripalimab Versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Supplementary Fig. 2 The association of CD8+ TIL density and PD-L1 expression with tumor objective response.